IL17A and depressive symptom measurement: Similarly, Inan et al. demonstrated that blocking IL-17A not only prevented oxycodone-induced depression-like effects and hyperalgesia, but also reduced naloxone-precipitated withdrawal signs and normalized the increase in cytokine levels in the ventral tegmental area (VTA) [61].